Albireo to Present at Investor Conferences in April

Date : 04/01/2019 @ 11:30AM
Source : GlobeNewswire Inc.
Stock : Albireo Pharma Inc (ALBO)
Quote : 20.81  -0.59 (-2.76%) @ 10:59PM
After Hours
Last Trade
Last $ 20.81 ◊ 0.00 (0.00%)

Albireo to Present at Investor Conferences in April

Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart

1 Year : From Dec 2018 to Dec 2019

Click Here for more Albireo Pharma Charts.

Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will present at the following investor conferences in April:

H.C. Wainwright & Co. Global Life Sciences ConferenceLocation: LondonPresentation date / time: Monday, April 8, 3:10 p.m. BST / 10:10 a.m. EDTPresenter: Ron Cooper, President and Chief Executive Officer

18th Annual Needham & Company Healthcare ConferenceLocation: New York CityPresentation date / time: Wednesday, April 10, 9:20 a.m. EDTPresenter: Simon Harford, Chief Financial Officer

A live audio webcast of each presentation will be accessible from the Media & Investors page of Albireo’s website, ir.albireopharma.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay in the Events & Presentations section of the Media & Investors page of Albireo’s website for at least two weeks following the event.

About Albireo Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo’s lead product candidate, A4250, is being developed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis. Albireo’s clinical pipeline also includes two Phase 2 product candidates. Albireo’s elobixibat, approved in Japan for the treatment of chronic constipation, is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world. Albireo was spun out from AstraZeneca in 2008.

Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.

Investor Contact: Hans Vitzthum, LifeSci Advisors, LLC, 212-915-2568Media Contact: Heather Anderson, 6 Degrees, 980-938-0260, handerson@6degreespr.com

Source: Albireo Pharma, Inc.

Latest ALBO Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.